Overview

Activated Protein C to Treat Acute Lung Injuries

Status:
Terminated

Trial end date:
2007-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the efficacy of activated Protein C (Xigris) for improving clinical outcomes in individuals with acute lung injury (ALI).

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Drotrecogin alfa activated
Protein C